The U.S. Food and Drug Administration (FDA) has commenced publishing complete response letters—which detail reasons for rejecting drug applications—in real time alongside companies' receipt of these letters. This policy, championed by FDA Commissioner Marty Makary, aims to enhance transparency and public trust in regulatory decisions. The move is aligned with directives promoting openness in scientific communications and marks a significant shift in FDA's disclosure practices, potentially impacting how pharmaceutical companies and the public access drug approval data.